In another phase I study (NCT02157792), the combination of VX-970 with cisplatin in patients with advanced TNBC and HR+/HER2– breast cancer achieved an objective response rate of 23.4% in the TNBC cohort, including a complete response rate of 4.3% and a partial response rate of 19.1%, with a disease control rate as high as 61.7% (Sofianidi et al., 2024). The gene discussed is ERBB2; the disease is breast carcinoma.